- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06441643
Rocklatan nové generace
Fáze II, prospektivní, dvoustupňová, dvojitě maskovaná, randomizovaná, multicentrická, kontrolovaná studie s odezvou na dávku hodnotící bezpečnost a oční hypotenzní účinnost očních roztoků AR-17043 a PG043 (AR-17043/latanoprost) u subjektů Se zvýšeným nitroočním tlakem
The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Přehled studie
Postavení
Podmínky
Detailní popis
The study consists of two sequential stages under a single protocol. Stage 1 and Stage 2 will enroll independent participant cohorts. Subject enrolled in Stage 1 will not be eligible to participate in Stage 2.
During Stage 1, approximately 100 adult subjects with OAG or OHT will be randomized to 5 arms: 3 different concentrations of AR-17043, placebo comparator, or netarsudil 0.02% (Rhopressa®) for a treatment duration of 7 days.
During Stage 2, approximately 350 adult subjects with OAG or OHT will be randomized to 5 arms: low and high concentrations of PG043 (AR-17043/latanoprost 0.005%), AR-17043 high concentration, latanoprost, or netarsudil 0.02%/latanoprost 0.005% (Rocklatan®) for a treatment duration of 28 days.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
Alabama
-
Dothan, Alabama, Spojené státy, 36301
- Trinity Research Group
-
-
Arizona
-
Phoenix, Arizona, Spojené státy, 85003
- Eye Doctors of Arizona
-
-
California
-
Garden Grove, California, Spojené státy, 92843
- Orange County Ophthalmology Medical Group
-
Inglewood, California, Spojené státy, 90301
- United Medical Research Institute
-
Newport Beach, California, Spojené státy, 92663
- Eye Research Foundation
-
Petaluma, California, Spojené státy, 94954
- North Bay Eye Associates
-
-
Colorado
-
Fort Collins, Colorado, Spojené státy, 80528
- Eye Center of Northern Colorado, PC
-
-
Florida
-
Delray Beach, Florida, Spojené státy, 33484
- Glaucoma Specialists of South Florida
-
Delray Beach, Florida, Spojené státy, 33484
- Bruce A. Segal MD
-
Lakeland, Florida, Spojené státy, 33805
- Central Florida Eye Associates
-
Mt. Dora, Florida, Spojené státy, 32757
- Mid Florida Eye Center
-
Venice, Florida, Spojené státy, 34285
- Center For Sight
-
-
Georgia
-
Roswell, Georgia, Spojené státy, 30076
- Coastal Research Associates
-
-
Missouri
-
Kansas City, Missouri, Spojené státy, 64154
- Moyes Eye Center
-
-
New York
-
Rochester, New York, Spojené státy, 14618
- Rochester Ophthalmological Group
-
-
North Carolina
-
Winston-Salem, North Carolina, Spojené státy, 27101
- James D. Branch Ophthalmology
-
-
North Dakota
-
Fargo, North Dakota, Spojené státy, 58103
- Bergstrom Eye Research
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy, 45242
- Cincinnati Eye Institute
-
Cincinnati, Ohio, Spojené státy, 45236
- Midwest Eye Center
-
-
Pennsylvania
-
Cranberry Township, Pennsylvania, Spojené státy, 16066
- Scott & Christie and Associates, PC
-
-
South Carolina
-
Mt. Pleasant, South Carolina, Spojené státy, 29464
- Carolina Eyecare Physicians LLC
-
-
Tennessee
-
Maryville, Tennessee, Spojené státy, 37803
- University Eye Specialists
-
Memphis, Tennessee, Spojené státy, 38119
- Total Eye Care PA
-
-
Texas
-
Dallas, Texas, Spojené státy, 75243
- Key-Whitman Eye Center
-
-
Virginia
-
Lynchburg, Virginia, Spojené státy, 24502
- Piedmont Eye Center
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Stage 1 Key Inclusion Criteria;
- Diagnosis of OAG or OHT in both eyes.
- High unmedicated IOP measurements in the study eye as specified in the protocol.
- Corrected visual acuity equal to or better than +1.0 logMAR (Snellen equivalent equal to or better than 20/200) in the study eye.
- Other protocol-specified inclusion criteria may apply.
Stage 2 Key Inclusion Criteria:
- Diagnosis of OAG or OHT in both eyes.
- High unmedicated IOP measurements in the study eye as specified in the protocol.
- Corrected visual acuity equal to or better than +0.7 logMAR (Snellen equivalent equal to or better than 20/100) in the study eye.
- Other protocol-specified inclusion criteria may apply.
Stage 1 and Stage 2 Key Exclusion Criteria:
- Current use of more than 2 ocular hypotensive medications within 30 days (either eye).
- Intraocular pressure greater than 36 millimeters mercury (mmHg) at Screening.
- Glaucoma other than OAG.
- Previous glaucoma surgery.
- Any abnormality preventing reliable measurements.
- Unable to demonstrate proper eyedrop instillation.
- Other protocol-specified exclusion criteria may apply.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: AR-17043 low concentration (Stage 1)
AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
Investigational monotherapy |
|
Experimentální: AR-17043 medium concentration (Stage 1)
AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
Investigational monotherapy |
|
Experimentální: AR-17043 high concentration (Stage 1)
AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
Investigational monotherapy |
|
Komparátor placeba: AR-17043 vehicle (Stage 1)
AR-17043 Vehicle, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
Placebo comparator |
|
Aktivní komparátor: Rhopressa (Stage 1)
Netarsudil 0.02% Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
Marketed monotherapy
Ostatní jména:
|
|
Experimentální: PG043 low concentration (Stage 2)
PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
Investigational fixed dose combination |
|
Experimentální: PG043 high concentration (Stage 2)
PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
Investigational fixed dose combination |
|
Aktivní komparátor: AR-17043 high concentration (Stage 2)
AR-17043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
Investigational monotherapy |
|
Aktivní komparátor: Latanoprost (Stage 2)
Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
Marketed monotherapy
Ostatní jména:
|
|
Aktivní komparátor: Rocklatan (Stage 2)
Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
Marketed fixed dose combination
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Mean diurnal IOP at Day 8 (Stage 1)
Časové okno: Day 8 (8:00, 10:00, 12:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. Diurnal IOP will be calculated as the average of the four measurements. |
Day 8 (8:00, 10:00, 12:00, 16:00)
|
|
Mean diurnal IOP at Day 29 (Stage 2)
Časové okno: Day 29 (8:00, 10:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. Diurnal IOP will be calculated as the average of the three measurements. |
Day 29 (8:00, 10:00, 16:00)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Mean IOP at each post-treatment timepoint (Stage 1)
Časové okno: Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint. |
Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
|
Mean change from the diurnally adjusted baseline IOP at each post-treatment timepoint (Stage 1)
Časové okno: Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint and compared to the time-relevant (corresponding) baseline measurement. Baseline is defined as the last visit prior to initiation of treatment. |
Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
|
Mean percent change from diurnally adjusted baseline IOP at each post-treatment timepoint (Stage 1)
Časové okno: Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint and compared to the time-relevant (corresponding) baseline measurement. Baseline is defined as the last visit prior to initiation of treatment. |
Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
|
Mean change from baseline mean diurnal IOP at each post-treatment timepoint (Stage 1)
Časové okno: Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. The baseline mean diurnal IOP will be calculated as the average of the four baseline measurements. Baseline is defined as the last visit prior to initiation of treatment. |
Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
|
Mean percent change from baseline mean diurnal IOP at each post-treatment timepoint (Stage 1)
Časové okno: Baseline (8:00, 10:00, 12:00, 16:00); Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. The baseline mean diurnal IOP will be calculated as the average of the four baseline measurements. Baseline is defined as the last visit prior to initiation of treatment. |
Baseline (8:00, 10:00, 12:00, 16:00); Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
|
Mean IOP at each post-treatment timepoint (Stage 2)
Časové okno: Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint. |
Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
|
Mean change from the diurnally adjusted baseline IOP at each post-treatment timepoint (Stage 2)
Časové okno: Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint and compared to the time-relevant (corresponding) baseline measurement. Baseline is defined as the last visit prior to initiation of treatment. |
Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
|
Mean percent change from diurnally adjusted baseline IOP at each post-treatment timepoint (Stage 2)
Časové okno: Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint and compared to the time-relevant (corresponding) baseline measurement. Baseline is defined as the last visit prior to initiation of treatment. |
Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
|
Mean change from baseline mean diurnal IOP at each post-treatment timepoint (Stage 2)
Časové okno: Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. The baseline mean diurnal IOP will be calculated as the average of the three baseline measurements. Baseline is defined as the last visit prior to initiation of treatment. |
Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
|
Mean percent change from baseline mean diurnal IOP at each post-treatment timepoint (Stage 2)
Časové okno: Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. The baseline mean diurnal IOP will be calculated as the average of the three baseline measurements. Baseline is defined as the last visit prior to initiation of treatment. |
Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Clinical Trial Lead, Pharma, Alcon Research, LLC
Publikace a užitečné odkazy
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Oční nemoci
- Glaukom
- Glaukom, otevřený úhel
- Oční hypertenze
- Farmaceutická řešení
- Farmaceutické přípravky
- Mastné kyseliny
- Lipidy
- Farmakologické akce
- Chemické účinky a použití
- Terapeutická použití
- Biologické faktory
- Řešení
- Speciální použití chemikálií
- Prostaglandiny F, syntetické
- Prostaglandiny, syntetické
- Prostaglandiny
- Eikosanoidy
- Mastné kyseliny, nenasycené
- Autakoidy
- Mediátory zánětu
- Latanoprost
- Oftalmologická řešení
- Netarsrudil
Další identifikační čísla studie
- GLR305-E001
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .